论文信息 - British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. - 字舞流文

British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary.

P. Merkel | E. Matteson | G. Reynolds | F. Buttgereit | C. Mallen | S. Mackie | E. Brouwer | R. Luqmani | W. Schmidt | H. Direskeneli | M. Bukhari | B. Dasgupta | M. Cimmino | A. Mahr | P. Lanyon | C. Dejaco | S. Ytterberg | R. Watts | M. Cid | C. Mukhtyar | S. Appenzeller | J. Mason | S. Mollan | D. Camellino | C. Duftner | K. Gilbert | L. Neill | Madeline Whitlock | M. Sandovici | E. Yacyshyn | T. Kermani | S. Gonzalez-Chiappe | A. D. de Souza | Dorothy Byrne | Asad Khan | E. O. Sullivan | E. Sullivan | M. Whitlock | Lorna Neill | P. Merkel

[1] C. Juhl,et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis , 2018, Annals of the rheumatic diseases.

[2] A. Iagnocco,et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice , 2018, Annals of the rheumatic diseases.

[3] Raveendhara R. Bannuru,et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis , 2017, Arthritis & rheumatology.

[4] J. Stone,et al. Trial of Tocilizumab in Giant‐Cell Arteritis , 2017, The New England journal of medicine.

[5] J. Krischer,et al. A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis , 2017, Arthritis & rheumatology.

[6] S. Reichenbach,et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[7] K. Barraclough,et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2015, Annals of the rheumatic diseases.

[8] M. Alba,et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation) , 2013, Annals of the rheumatic diseases.

[9] A. Morgan,et al. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis , 2012, Annals of the rheumatic diseases.

[10] J. Lie. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. , 2010, Arthritis and rheumatism.

[11] K. Barraclough,et al. BSR and BHPR guidelines for the management of giant cell arteritis. , 2010, Rheumatology.

[12] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[13] H. Raspe,et al. EULAR recommendations for the management of large vessel vasculitis , 2008, Annals of the rheumatic diseases.

[14] L. Smeeth,et al. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001 , 2006, Annals of the rheumatic diseases.

[15] C. Weyand,et al. Giant-Cell Arteritis and Polymyalgia Rheumatica , 2003, Annals of Internal Medicine.

[16] G. Smetana,et al. Does this patient have temporal arteritis? , 2002, JAMA.

[17] M. Delgado-Rodríguez,et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. , 1998, Arthritis and rheumatism.

[18] K. Barraclough,et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. , 2010, Rheumatology.